Paranal Observatory

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023

Retrieved on: 
Tuesday, February 20, 2024
Biotechnology, General Health, Health, Pharmaceutical, Oncology, NSCLC, Paranal Observatory, Cohort, EGFR, Research, Neoplasm, Forecasting, Immunotherapy, ASCO, Investment, FDA, SITC, Table, PD-1, SMMT, Society, Annual general meeting, IPR, Lung cancer, GAAP, VEGF, The Wall Street Journal, Tumor microenvironment, Webcast, Patient, Phase, Trial of the century, Summit, TKI, Pharmaceutical industry

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the fourth quarter and year-ended December 31, 2023.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the fourth quarter and year-ended December 31, 2023.
  • Summit received the rights to develop and commercialize ivonescimab in the United States, Canada, Europe, and Japan.
  • In exchange for these rights, Summit made an upfront payment of $500 million in 2023.
  • Non-GAAP R&D expenses were $22.4 million for the fourth quarter of 2023, as compared to $4.4 million for the same period of the year period.

Summit Therapeutics Announces Updated Phase II Data for Ivonescimab at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 8, 2024
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Marketing, JPM, Survival, Paranal Observatory, HKEX, EGFR, CDE, Clinical trial, Standard of care, Neoplasm, TPS, Summit, Investment, Patient, Pharmaceutical industry

The aforementioned data related to AK112-201 was generated and analyzed by Akeso.

Key Points: 
  • The aforementioned data related to AK112-201 was generated and analyzed by Akeso.
  • Both studies represent ivonescimab in randomized, pivotal clinical trials against the standard of care in their respective settings.
  • “As the data continues to mature in Phase II studies evaluating ivonescimab, including data related to the survival of patients impacted by these terrible diseases, our belief and conviction in ivonescimab is reinforced,” stated Summit’s Chief Executive Officers, Robert W. Duggan and Dr. Maky Zanganeh.
  • We believe that the potential created by the differentiated mechanism of action and supporting trial data for ivonescimab deserves a swift development plan to bring ivonescimab to those patients who can benefit most.

Ivonescimab’s Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023

Retrieved on: 
Tuesday, October 31, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, TKI, Patient, HKEX, Research, VEGF, SMMT, NSCLC, Drug discovery, Lung cancer, PD-1, Doctor of Philosophy, Summit, Poster, Senior, Phase, SITC, Immunotherapy, Paranal Observatory, Tumor microenvironment, Safety, Society, TME, EGFR, Pharmaceutical industry

The poster with updated data describing ivonescimab’s mechanism of action will be displayed on Saturday November 4, 2023, from 11:55am to 1:25pm Pacific Time.

Key Points: 
  • The poster with updated data describing ivonescimab’s mechanism of action will be displayed on Saturday November 4, 2023, from 11:55am to 1:25pm Pacific Time.
  • The poster is a collaborative effort between Summit and our collaboration and licensing partner, Akeso, Inc. (HKEX Code: 9926.HK), who generated and analyzed the data.
  • The poster describes how ivonescimab displays unique cooperative binding to each of its intended targets with higher affinity when in the presence of both PD-1 and VEGF.
  • Lung cancer is believed to impact approximately 238,0004 people in the United States each year and approximately 477,0005 in Europe.

Promising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023

Retrieved on: 
Sunday, June 4, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Histology, Progression-free survival, Cohort, Neoplasm, DOR, Survival, OS, Sun, Trae tha Truth, Lung cancer, Constipation, TKI, NSCLC, Paranal Observatory, Immunotherapy, PFS, Trial of the century, ASCO, ORR, VEGF, Hair, HKEX, American Society of Clinical Oncology, Patient, EGFR, Anaplastic lymphoma kinase, Anemia, Annual general meeting, TME, SMMT, Poster, PD-1, Phase, Summit, Tumor microenvironment, Society, Safety, ALK, Pharmaceutical industry

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced promising data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, that is being presented today from 8:00 to 11:00am at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced promising data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, that is being presented today from 8:00 to 11:00am at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.
  • AK112-201 (NCT04736823) is an open-label Phase II study evaluating ivonescimab plus chemotherapy for 174 patents across three cohorts of patients.
  • After a median follow-up time of 13.3 months, median overall survival (OS) was not reached; although, estimated 9-month OS was 93.2%.
  • Over 750 patients have been treated with ivonescimab across multiple clinical studies in different indications in China and Australia.

Ivonescimab Updated Data to be Featured at ASCO 2023

Retrieved on: 
Thursday, June 1, 2023
Oncology, Medical Supplies, Health, Other Health, General Health, Pharmaceutical, Biotechnology, Metastasis, Sun, Lung cancer, TKI, NSCLC, Central Time, Paranal Observatory, Immunotherapy, Trial of the century, ASCO, VEGF, HKEX, American Society of Clinical Oncology, Patient, EGFR, Anaplastic lymphoma kinase, TME, Annual general meeting, SMMT, Poster, PD-1, Phase, Summit, Tumor microenvironment, Society, Safety, ALK, Pharmaceutical industry, Medical imaging

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.
  • The poster with updated clinical data from Phase II clinical trials will be displayed on Sunday June 4 from 8:00 to 11:00am Central Time during the Lung Cancer – Non-Small Cell Metastatic Poster Session.
  • The poster provides updated data supporting promising anti-tumor activity of ivonescimab in first line advanced or metastatic NSCLC, while displaying that ivonescimab may have an acceptable safety profile in combination with platinum-doublet chemotherapy for patients with squamous or non-squamous advanced or metastatic NSCLC in this clinical study.
  • Over 750 patients have been treated with ivonescimab across multiple clinical studies in different indications in China and Australia.

Summit Therapeutics Announces First Patient Treated in Phase III HARMONi Clinical Trial Evaluating Ivonescimab (SMT112)

Retrieved on: 
Tuesday, May 9, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Progression-free survival, Lung cancer, TKI, NSCLC, Carboplatin, Immunotherapy, Institutional review board, PFS, Trial of the century, VEGF, Patient, EGFR, TME, SMMT, Neoplasm, PD-1, FDA, Courage, Phase, Pemetrexed, Tumor microenvironment, Safety, Pharmaceutical industry, Nursing, Medical imaging, Paranal Observatory

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the first United States-based patient has been enrolled in the Phase III HARMONi study.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the first United States-based patient has been enrolled in the Phase III HARMONi study.
  • HARMONi is a Phase III multiregional, randomized, double-blinded study.
  • Specifically, the study will compare ivonescimab combined with pemetrexed and carboplatin chemotherapies against a placebo plus pemetrexed and carboplatin.
  • Over 750 patients have been treated with ivonescimab across multiple clinical studies in China and Australia.

Summit Therapeutics Announces Initial Indications for Clinical Trials for Ivonescimab (SMT112)

Retrieved on: 
Wednesday, May 3, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, US Food Sovereignty Alliance, Quality of life, TKI, NSCLC, Paranal Observatory, Lung cancer, Immunotherapy, VEGF, Patient, EGFR, TME, SMMT, Knowledge, PD-1, FDA, Tumor microenvironment, Food, Safety, Pharmaceutical industry

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it has determined its first two indications in non-small cell lung cancer (NSCLC) in which to pursue Phase III clinical trials for its innovative, potential first-in-class bispecific antibody, ivonescimab.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it has determined its first two indications in non-small cell lung cancer (NSCLC) in which to pursue Phase III clinical trials for its innovative, potential first-in-class bispecific antibody, ivonescimab.
  • “I am immensely proud of the speed and efficiency of our team to enable clinical trials for SMT112,” stated Robert W. Duggan, Chairman & Chief Executive Officer of Summit.
  • “I am particularly enthusiastic about the potential of ivonescimab: this shared enthusiasm is the impetus behind Team Summit’s rapid development to enter into multiple Phase III clinical trials with SMT112.
  • Team Summit exists to pose, strategize, and execute a path forward in medicinal therapeutic health care that places Summit in a well-deserved, top market share, leadership position.